Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.chom.2020.05.007 http://scihub22266oqcxt.onion/10.1016/j.chom.2020.05.007 32411313!7221383!32411313     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Host+Microbe 2020 ; 28 (1): 117-123.e1 Nephropedia Template TP {{tp|p=32411313|t=2020. Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis |pdf=|usr=}}{{32411313}} gab.com Text Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis JO: Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=32411313 #FOAvip Dysregulation of inflammation is hypothesized to play a crucial role in the severe complications of COVID-19, with the IL-1/IL-6 pathway being central. Here, we report on the treatment of eight severe COVID-19 pneumonia patients-seven hospitalized in intensive care units (ICUs) in Greece and one non-ICU patient in the Netherlands-with the interleukin-1 receptor antagonist Anakinra. All patients scored positive for the hemophagocytosis score (HScore) and were diagnosed with secondary hemophagocytic lymphohistocytosis (sHLH) characterized by pancytopenia, hyper-coagulation, acute kidney injury, and hepatobiliary dysfunction. At the end of treatment, ICU patients had less need for vasopressors, significantly improved respiratory function, and lower HScore. Although three patients died, the mortality was lower than historical series of patients with sHLH in sepsis. These data suggest that administration of Anakinra may be beneficial for treating severe COVID-19 patients with sHLH as determined by the HScore, and they support the need for larger clinical studies to validate this concept. Twit Text FOAVip Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis ????Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=32411313 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32411313 #FOAvip English Wikipedia <ref>{{Cite pmid|32411313}}</ref> Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis #MMPMID32411313 Dimopoulos G; de Mast Q; Markou N; Theodorakopoulou M; Komnos A; Mouktaroudi M; Netea MG; Spyridopoulos T; Verheggen RJ; Hoogerwerf J; Lachana A; van de Veerdonk FL; Giamarellos-Bourboulis EJ Cell Host Microbe 2020[Jul]; 28 (1): 117-123.e1 PMID32411313show ga Dysregulation of inflammation is hypothesized to play a crucial role in the severe complications of COVID-19, with the IL-1/IL-6 pathway being central. Here, we report on the treatment of eight severe COVID-19 pneumonia patients-seven hospitalized in intensive care units (ICUs) in Greece and one non-ICU patient in the Netherlands-with the interleukin-1 receptor antagonist Anakinra. All patients scored positive for the hemophagocytosis score (HScore) and were diagnosed with secondary hemophagocytic lymphohistocytosis (sHLH) characterized by pancytopenia, hyper-coagulation, acute kidney injury, and hepatobiliary dysfunction. At the end of treatment, ICU patients had less need for vasopressors, significantly improved respiratory function, and lower HScore. Although three patients died, the mortality was lower than historical series of patients with sHLH in sepsis. These data suggest that administration of Anakinra may be beneficial for treating severe COVID-19 patients with sHLH as determined by the HScore, and they support the need for larger clinical studies to validate this concept. |*Betacoronavirus[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19[MESH] |Comorbidity[MESH] |Coronavirus Infections/*complications/*drug therapy[MESH] |Female[MESH] |Humans[MESH] |Interleukin 1 Receptor Antagonist Protein/*therapeutic use[MESH] |Lymphohistiocytosis, Hemophagocytic/*drug therapy/etiology[MESH] |Male[MESH] |Middle Aged[MESH] |Off-Label Use[MESH] |Oxygen/blood[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/*drug therapy[MESH] |Respiratory Insufficiency/prevention & control[MESH]Favorable Anakinra Responses in Severe Covid-19 Patients with Secondar(epmc).pdf DeepDyve Pubget Overpricing